XZP-3621

· Xuanzhu Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for XZP-3621, covering 2022-01-24 to 2025-07-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer [Phase 1]

See pricing